NephroPlus has undertaken a broad study to simplify the complexities and understand the impact of COVID-19 on dialysis patients and the benefits of vaccination.

The study published in Nephrology Journal, Kidney International Reports, finally bridges the gap between speculation and scientific fact. It also brings to bear the magnitude and severity of COVID-19, especially on patients undergoing dialysis.

NephroPlus also studied vaccination and the rate of infections, hospitalisations, and mortality among vaccinated patients across India, with findings showing that vaccines are truly effective against COVID-19.

According to the Principal Investigator, Dr Vivekanand Jha, the study showed that infections, hospitalisations, and mortality were all significantly reduced among people who had taken at least one dose of the vaccine. 

Dr Jha added, "We found that COVID-19 infection among patients on dialysis was 20-fold greater than that reported in the general population when adjusted for age and sex. While it was 8.7 per cent among dialysis patients during the study period, the infection among the general population stood at 0.44 per cent during the same period”.

Kamal D Shah, Co-Founder, NephroPlus and a co-author of the study says, “It is important for dialysis patients to know that they have a high risk of contracting this lethal virus and die if they don’t take the vaccine. That is what our study shows."